Granules India Share Price
847.45-6.40 (-0.75%)
+63.46% past 1 Year
News
Granules gains comfort as FDA clears corrective actions at Gagillapur unit
Equity
GRANULES
Granules India Q1 revenue rises to Rs 1,500 crore versus Rs 1,200 crore year on year
Equity
GRANULES
Granules India Q1 PAT surges 63 percent, beats FY27 growth guidance
Equity
GRANULES
Granules India Q1 EBITDA rises strongly year-on-year with margin expansion
Equity
GRANULES
Granules India Q1 consolidated net profit jumps sharply on YoY basis
Equity
GRANULES
Granules India sees Rs 16.49 crores NSE block trade at Rs 890.90
Equity
GRANULES
Granules India secures sole First-to-File ANDA for US narcolepsy drug
Equity
GRANULES
Granules India informs about analyst meet
Equity
GRANULES
Granules India surges as its arm receives Establishment Inspection Report from USFDA
Equity
GRANULES
Granules India informs about press release
Equity
GRANULES
Granules India unit gets US FDA EIR after Chantilly plant inspection
Equity
GRANULES
Granules India sees Rs 16.12 crores NSE block trade at Rs 784.10 per share
Equity
GRANULES
Granules India sees Rs 41.76 crores NSE block trade at Rs 760.15
Equity
GRANULES
Granules India sees Rs 38.5 crores NSE block trade at set premium price
Equity
GRANULES
Granules India sees Rs 21.32 crores NSE block trade at set price level
Equity
GRANULES
Granules India sees Rs 118.48 crores NSE block trade at Rs 760
Equity
GRANULES
Granules India gains on reporting 33% rise in Q4 consolidated net profit
Equity
GRANULES
Granules India Plans 1-2 New Controlled Substance Products Yearly, 9 US FDA Applications Pending.
Equity
GRANULES
Granules India Expects Stable Net Debt in FY '27 Amid Capex and Working Capital Pressures.
Equity
GRANULES
Granules India targets positive FY27 performance for peptide CDMO platform amid quarterly volatility
Equity
GRANULES